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Background: Parkinson’s disease is an irreversible neurodegenerative disease linked to progressive movement
disorders and is accompanied by an inflammatory reaction that is believed to contribute to its pathogenesis. Since
sensitivity to inflammation is not the same in all brain structures, the aim of this work was to test whether physiological
conditions as stress could enhance susceptibility to inflammation in the substantia nigra, where death of dopaminergic
neurons takes place in Parkinson’s disease.
Methods: To achieve our aim, we induced an inflammatory process in nonstressed and stressed rats (subject to a
chronic variate stress) by a single intranigral injection of lipopolysaccharide, a potent proinflammogen. The effect of
this treatment was evaluated on inflammatory markers as well as on neuronal and glial populations.
Results: Data showed a synergistic effect between inflammation and stress, thus resulting in higher microglial activation
and expression of proinflammatory markers. More important, the higher inflammatory response seen in stressed animals
was associated with a higher rate of death of dopaminergic neurons in the substantia nigra, the most characteristic
feature seen in Parkinson’s disease. This effect was dependent on glucocorticoids.
Conclusions: Our data demonstrate that stress sensitises midbrain microglia to further inflammatory stimulus. This
suggests that stress may be an important risk factor in the degenerative processes and symptoms of Parkinson’s disease.
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Parkinson’s disease (PD) is an age-related neurodegener-
ative disorder characterised by progressive degeneration
of the nigrostriatal dopaminergic (DAergic) neurons of
the substantia nigra pars compacta (SNpc) [1]. This
process results in extrapyramidal motor dysfunction
accompanied by progressive impairment of autonomy,
mood and cognitive function [1-3]. Although some genes
have been identified as being responsible for rare familial
early-onset PD [4], the aetiology of PD remains elusive.
Oxidative stress, reduced expression of trophic factors,
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unless otherwise stated.proteasome system and neuroinflammatory mechanisms
are thought to collaborate in the progressive demise of
SNpc neurons [1,2,5-11].
Evidence suggesting that inflammation may play a
central role in the cell loss in PD has been accumulating
since the presence of activated microglia in the substan-
tia nigra (SN) of PD patients was first reported ([12]; for
review, see [13,14]). The increased number of activated
microglial cells is accompanied by increased expression of
proinflammatory cytokines [6,15]. Inflammation has been
shown to exist in different animal models of PD, including
those using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), 6-hydroxydopamine (6-OHDA) or rotenone
[16-19]. Lipopolysaccharide (LPS) is the active immu-
nostimulant in the cell wall of Gram-negative bacteria
that is responsible for triggering the cascade of events
following bacterial infection [20,21]. Subtoxic doses ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of PD [22], supporting the hypothesis that brain inflam-
mation may play a significant role in PD progression.
More important, epidemiological studies have demon-
strated that the incidence of idiopathic PD is about 50%
lower in chronic users of nonsteroidal anti-inflammatory
drugs and cyclooxygenase inhibitors than in age-matched
nonusers [23-25].
Our group pioneered in showing that an inflammatory
response induced by the intracerebral injection of LPS
can cause neuronal death, specifically in the nigrostriatal
DAergic system [26-28]. Interestingly, the SN, compared
with other brain areas, is especially susceptible to LPS-
induced neurotoxicity [28]. In this structure, the strong
microglial response to LPS preceded the death of
DAergic neurons [26,29]. This point has been confirmed
by experiments with chronic infusion of LPS into the SN
that produced delayed death of DAergic neurons, as also
found in PD [17]. Under these conditions, microglial
activation reached a plateau 2 weeks earlier than the
appearance of degenerative events on the DAergic system
[17]. The neurotoxic effect of LPS has been also observed
in mesencephalic cell cultures [30-33].
Some physiological conditions might enhance the in-
flammatory response to LPS and account for the diver-
sity in symptoms and course of PD, as well as for
individuals’ responses to medication after the onset of
PD [34]. Stress is widely acknowledged to be a predis-
posing and precipitating factor in psychiatric illnesses
[35,36] and some neurodegenerative diseases. It was one
of the earliest proposed causes of PD [37,38]. Stress is a
condition of human experience that includes not only
major life events but also the hassles of daily life that
elevate activities of physiological systems, which causes
disruption of ongoing homeostasis. It reflects both indi-
vidual experience and genetic background; therefore, re-
actions to a stressful incident are highly variable [39,40].
Exposure to a stressful situation leads to the activation
of two systems: the sympathoadrenomedullary system
and the hypothalamic-pituitary-adrenal (HPA) axis (for
review, see [41]). The former leads to increased circulat-
ing levels of adrenaline, whereas the latter leads to
release of corticosteroid hormones from the adrenal cor-
tex. Corticosteroid hormones can easily enter the brain
because of their lipophilic properties and bind two types
of receptors: mineralocorticoid receptors (MRs) and
glucocorticoid receptors (GRs) (for review, see [42]).
Whereas MRs have a high affinity for the endogenous
hormone corticosterone, GRs have a lower affinity.
Interestingly, MRs are restricted mainly to limbic re-
gions, including the amygdala and all subareas of the
hippocampus. On the contrary, GRs are ubiquitously
distributed in neurons and glia. Although stress can be
beneficial in its acute phase, repeated and severe stressfulstimuli produce adverse effects on neuronal functions,
especially in those structures involved in the stress
response, such as the hypothalamus, prefrontal cortex
(PFC) and hippocampus.
We have previously shown a synergistic deleterious
effect of chronic stress and inflammation in limbic struc-
tures such as the hippocampus [43] and the PFC [44].
These studies suggest that stress strongly sensitises
microglial cells to proinflammatory stimuli. However,
whether this effect is generalised in the whole central
nervous system (CNS) is unknown. The aim of the
present work was to elucidate whether enhancement
of the LPS-induced damage by chronic stress is exten-
sible to other CNS structures, especially to those involved
in neurodegenerative disorders such as PD, in which in-
flammation seems to play an important role. To evaluate
this hypothesis, we tested whether chronic variate stress
could enhance the damage induced by LPS in the SN. We
combined immunohistochemical and molecular biological
techniques in an effort to elucidate the effects of chronic
stress, intranigral LPS injection and a combination of both
on different cell types in the SN. We found that stress
significantly increased the inflammatory damage induced
by LPS. We also studied the effect produced on the
different parameters assayed by RU486 (mifepristone (11β-
[p-(dimethylamino)phenyl]-17β-hydroxy-17-(1-propynyl)
estra-4,9-dien-3-one)), a potent inhibitor of GR activation.
Methods
Animals and surgery
Male albino Wistar rats (250 to 270 g) were used for
these studies. The rats were kept at constant room
temperature of 22°C ± 1°C and 60%relative humidity on
a 12:12-hour light–dark cycle with free access to food
and water. Rats were anaesthetized with chloral hydrate
(400 mg/kg) and positioned in a stereotaxic apparatus
(Kopf Instruments, Tujunga, CA, USA) to conform to
the brain atlas of Paxinos and Watson [45]. Injections
into the SN were made 5.5 mm posterior, 1.8 mm lateral
and 8.3 mm ventral to the bregma at day 1, 2 hours after
the application of the first stressor (Figure 1).
Experiments were carried out in accordance with the
Guidelines of the European Union Council (86/609/EU)
and Spanish regulations for the use of laboratory animals
(BOE 67/8509-12, 1988), and the study was approved by
the Scientific Committee of the University of Seville.
Five groups of animals were established according to
the different treatments: V, the vehicle/nonstressed con-
trol group, which received a single intranigral injection
of 2 μl of vehicle (Monastral Blue inert tracer, 1% in sa-
line solution; Sigma-Aldrich, St Louis, MO, USA) into
the left SN; S, the vehicle/stressed group, which were
treated with a single intranigral injection of 2 μl of ve-
hicle into the left SN and were stressed for 9 days; L, the
Figure 1 Experimental groups and treatments. Intranigral injections of vehicle (Veh) or lipopolysaccharide (LPS) were given at day 1. In the
stressed groups (S, SL and SLR), intranigral injections were carried out after the application of the first stressor (10 minutes of forced swimming).
In the SLR group, RU486 (mifepristone (11β-[p-(dimethylamino)phenyl]-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one)) was injected subcutaneously
every day 1 hour before the stressor. V, vehicle; S, stress; L, lipopolysaccharide; SL, lipopolysaccharide injected into stressed animals; SLR,
lipopolysaccharide injected into stressed animals treated with RU486.
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with a single intranigral injection of 2 μg of LPS (from
Escherichia coli serotype 026:B6; Sigma-Aldrich) dissolved
in 2 μl of vehicle (1% Monastral Blue inert tracer in saline
solution) into the left SN; SL, the LPS/stressed group,
which were treated with a single intranigral injection of
2 μg of LPS and stressed for 9 days; SLR, the LPS/
stressed/RU486 group, which were treated with a single
intranigral injection of 2 μg of LPS, stressed for 9 days and
were given a daily dose of 20 mg/kg RU486 in saline
with 20% dimethyl sulphoxide by subcutaneous injection
(Sigma-Aldrich) for 9 days 1 hour before exposure to
the stressors. All animals were killed by decapitationat 6 hours after surgery (RT-PCR experiments) or by
perfusion 10 days after surgery (immunohistochemistry
experiments). At least four animals were used for each
group.
Stress model
Chronic variate stress was adapted from other models of
variate stress [46-51] with modifications as reported pre-
viously [43,44]. Animals were divided into stressed and
nonstressed groups. Nonstressed animals were kept un-
disturbed in their home cages for 10 days. A 9-day vari-
ate stressor paradigm was used for the animals in the
stressed groups. The schedule of stressors is given in
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from day to day (between 08:00 and 20:00) to minimize
its predictability. Restraint was carried out by placing
each animal in a 21 cm× 6 cm plastic tube and adjusting
it with plaster tape on the outside, so that the animal was
unable to move. There was a 6-cm hole at the far end for
breathing. Forced swimming was carried out by placing
the animal in a glass tank measuring 44 × 33 × 30 cm
with 22 cm of water depth at 23°C ± 2°C. Body weight
was measured at the beginning and the end of the 10-day
treatment and was evaluated as an indirect parameter of
HPA axis activation.
Serum corticosterone measurement
Rats were deeply anaesthetized, and blood was collected
from the heart. Serum corticosterone concentration was
measured by enzyme-linked immunosorbent assay ac-
cording to the manufacturer’s instructions (Assay Designs
Correlate-EIA; Enzo Life Sciences, Farmingdale, NY, USA).
Immunohistological evaluation
Thaw-mounted 20-μm coronal sections were cut on a
cryostat at −15°C and mounted on gelatine-coated slides.
Primary antibodies used were rabbit-derived anti-tyrosine
hydroxylase (1:300 anti-TH; Sigma-Aldrich), mouse-
derived anti-glial fibrillary acidic protein (1:300 anti-GFAP;
EMD Millipore, Billerica, MA, USA), rabbit-derived anti-
Iba-1 (1:300; Wako Chemicals, Richmond, VA, USA) and
mouse-derived OX-6 (1:200; AbD Serotec, Raleigh, NC,
USA). Incubations and washes for all the antibodies
were carried out in Tris-buffered saline (TBS), pH 7.4.
All work was done at room temperature. Sections were
washed and then treated with 0.3% hydrogen peroxide
in methanol for 20 minutes, washed again, and incu-
bated in a TBS solution containing 1% horse serum
(Vector Laboratories, Burlingame, CA, USA) for GFAP
and OX-6 immunostaining or in a solution containingTable 1 Schedule of stressors used during the chronic
variate stress treatmenta
Day Stressor Time
1 Forced swimming 10 min
2 Restraint 3 h
3 Water deprivation 24 h
4 Restrain at 4ºC 90 min
5 Isolation 24 h
6 Food deprivation 24 h
7 Water deprivation 24 h
8 Restrain at 4ºC 2 h
9 Food deprivation 24 h
aAnimals subjected to stress were exposed to the stressors according to the
schedule listed. The left column indicates the day of the stressing protocol.
The right column indicates the length of each stimulus applied.goat serum (Vector Laboratories) for TH and Iba-1 immu-
nostaining for 60 minutes in a humidity chamber. Slides
were drained and further incubated with the primary anti-
body in TBS containing 1% horse or goat serum and
0.25% Triton X-100 for 24 hours. Sections were then incu-
bated for 2 hours with biotinylated horse anti-mouse
immunoglobulin G (IgG, 1:200; Vector Laboratories) for
GFAP and OX-6 immunostaining or biotinylated goat
anti-rabbit IgG (1:200; Vector Laboratories) for TH and
Iba-1 immunostaining. The secondary antibody was di-
luted in TBS containing 0.25% Triton X-100, and its
addition was preceded by three 10-minute rinses in
TBS. Sections were then incubated with ExtrAvidin–
Peroxidase buffered aqueous solution (1:100; Sigma-
Aldrich). The peroxidase was visualized by performing
a standard diaminobenzidine–hydrogen peroxide reaction
for 5 minutes.
Immunohistochemical data analysis
Analyses were carried out in a bounded region of the SN
with a length of 300 μm in the anteroposterior axis
centred at the point of injection (5.5 mm with respect to
the bregma), that is, between 5.35 and 5.65 mm with
respect to the bregma. In each case, five sections per
animal were used with random starting points and sys-
tematically distributed through the anteroposterior axis
of the analysed region. For the measurement of areas
lacking GFAP immunoreactivity, we used analySIS im-
aging software (Soft Imaging System GmbH, Münster,
Germany) coupled to a Polaroid DMC camera (Polaroid,
Cambridge, MA, USA) attached to a Leica light micro-
scope (Leica Microsystems, Wetzlar, Germany). To count
cells showing OX-6 immunoreactivity, we systematically
sampled the area occupied by the OX-6-positive cells in
each section from a random starting point with a grid
adjusted to count five fields per section. An unbiased
counting frame of a known area (40 × 25 μm= 1,000 μm2)
was superimposed on the tissue section image under a
100× oil immersion lens objective. The different types of
OX-6-positive cells (displaying different shapes, depending
on their activation state) were counted as a whole and
expressed as cells per millimetre squared. The number of
TH-positive neurons in the SN was estimated using a
fractionator sampling design [52]. Counts were carried
out at regular predetermined intervals within each section
(x = 150 μm and y = 200 μm). An unbiased counting frame
of known area (40 μm × 25 μm = 1,000 μm2) was
superimposed on the tissue section image under a
100× oil immersion lens objective. Therefore, the area
sampling fraction was 1,000/(150 × 200) = 0.033. The
entire z-dimension of each section was sampled; hence,
the section thickness sampling fraction was 1. In all ani-
mals, 20-μm sections, each 100 μm apart, were analysed;
thus, the fraction of sections sampled was 20/100 = 0.20.
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mated by multiplying the number of neurons counted
within the sample regions by the reciprocals of the area
sampling fraction and the fraction of section sampled.
Immunofluorescence
Animals were perfused and sections prepared as described
above. Incubations and washes for all the antibodies were
carried out in phosphate-buffered saline (PBS), pH 7.4. All
work was done at room temperature. For double-labelling
of Iba-1 with TH, sections were blocked with PBS con-
taining 1% normal horse serum (Vector Laboratories)
for Iba-1 and 1% goat serum (Vector Laboratories) for TH
for 1 hour. The slides were washed three times in PBS,
then incubated overnight at 4°C with either mouse-
derived anti-Iba-1 (1:300; EMD Millipore) and rabbit-
derived anti-TH (1:300; Sigma-Aldrich) diluted in PBS
containing 1% normal horse serum and 1% goat serum
and 0.25% Triton X-100. Sections were incubated with
horse anti-mouse secondary antibody conjugated to fluor-
escein (1:200; Vector Laboratories) for Iba-1 and goat
anti-rabbit secondary antibody conjugated to Alexa Fluor
594 (1:200; Molecular Probes/Invitrogen, Eugene, OR,
USA) for TH for 1 hour at 22°C ± 1°C in the dark, and
their addition was preceded by three 10-minute rinses in
PBS. Nuclei were counterstained with Hoechst dye (1 μg/
ml; Molecular Probes). As a control, another set of experi-
ments was performed whereby the sections were incu-
bated with only the Iba-1 antibody, then visualized with
both fluorescence filters. No signal was detected when
Iba-1 alone was used with an Alexa Fluor 594 filter
(photomicrograph not shown). The same was true with
TH when a fluorescein filter was used.
For double-labelling of Iba-1 with inhibitor of nuclear
factor κΒ (NF-κΒ) kinase, subunit β (IKKβ), sections
were blocked with PBS containing 1% normal goat
serum (Vector Laboratories) for Iba-1 and rabbit serum
(Invitrogen) for TH for 1 hour. The slides were washed
three times in PBS, then incubated overnight at 4°C
with either rabbit-derived anti-Iba-1 (1:300; Wako
Chemicals) and goat-derived anti-IKKβ (1:300; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) diluted in
PBS containing 1% normal goat and 1% rabbit serum
and 0.25% Triton X-100. Sections were incubated with
goat anti-rabbit secondary antibody conjugated to Alexa
Fluor 594 (1:200; Molecular Probes/Invitrogen) for Iba-1
and with rabbit anti-goat secondary antibody conjugated
to fluorescein (Vector Laboratories; 1:200) for IKKβ for
1 hour at 22°C ± 1°C in the dark. Their addition was pre-
ceded by three 10-minute rinses in PBS. Nuclei were
counterstained with Hoechst dye (1 μg/ml; Molecular
Probes/Invitrogen). As a control, another set of experi-
ments was performed whereby the sections were incu-
bated with only the Iba-1 antibody, then visualized withboth filters. No signal was detected when Iba-1 alone
with the fluorescein filter was used (photomicrograph
not shown). The same was true for IKKβ when an Alexa
Fluor 594 filter was used. Fluorescence images were ac-
quired using a Zeiss LSM 7 DUO confocal laser scanning
microscope (Carl Zeiss Microscopy, Jena Germany) and
processed using the associated software package (ZEN
2010; Carl Zeiss Microscopy).
Real time RT-PCR
The left SN was dissected from each rat 6 hours after the
injection of vehicle or LPS, snap-frozen in liquid nitrogen
and stored at −80 ºC. Total RNA was extracted from
the SN using the RNeasy kit (QIAGEN, Germantown,
MD, USA). cDNA was synthesized from 1 μg of total
RNA using the QuantiTect Reverse Transcription Kit
(QIAGEN) in 20 μl of reaction volume as described by
the manufacturer. Real-time PCR was performed with iQ
SYBR Green Supermix (Bio-Rad Laboratories, Hercules,
CA, USA), 0.4 μM primers and 1 μl of cDNA. Controls
were carried out without cDNA. Amplification was run in
a MasterCycler ep realplex thermal cycler (Eppendorf,
Happauge, NY, USA) at 94°C for 3 minutes, followed by
35 cycles at 94°C for 30 seconds, 55°C to 60°C for 45 s
and 72°C for 45 s, then by a final elongation step at 72°C
for 7 minutes. Following amplification, melting curve ana-
lysis was performed by heating the reactions from 65°C to
95°C at 1°C intervals while monitoring fluorescence. Ana-
lysis confirmed a single PCR product at the predicted
melting temperature. β-actin served as the reference gene
and was used for sample normalization. Primer sequences
for tumour necrosis factor α (TNF-α), interleukin 6 (IL-6),
IL-1β, inducible nitric oxide synthase (iNOS), CD200, che-
mokine (C-X3-C motif) receptor 1 (CX3CR1), monocyte
chemoattractant protein 1 (MCP-1) and β-actin are shown
in Table 2. The cycle at which each sample crossed a
fluorescence threshold cycle (Ct) was determined, and the
triplicate values for each cDNA were averaged. Analyses
of real-time PCR were carried out using a comparative Ct
method integrated into Bio-Rad system software.
Western blot analysis
SN was lysed in 15 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM
ethylene glycol tetraacetic acid and 1 mM phenylmethyl-
sulfonyl fluoride (all from Sigma-Aldrich). The hom-
ogenate was centrifuged at 12,000 × g for 20 minutes at
4°C. Protein content of the samples was estimated by the
method of micro-Lowry using bovine serum albumin as
a standard [59], and 25 μg of protein was loaded for
each lane. Protein samples were separated by SDS-PAGE
(10%) and transferred onto a nitrocellulose membrane
(Novex; Life Technologies, Grand Island, NY, USA).
Membranes were blocked with blocking buffer (5% milk in
Table 2 Primers used for RT-PCRa
Target mRNA Forward (F) and reverse (R) primers Reference
TNF-α F: 5′-TACTGAACTTCGGGGTGATTGGTCC-3′ [53]
R: 5′-CAGCCTTGTCCCTTGAAGAGAACC-3′
IL-6 F: 5′-AAAATCTGCTCTGGTCTTCTGG-3′ [54]
R: 5′-GGTTTGCCGAGTAGACCTCA-3′
β-actin F: 5′-TGTGATGGTGGGAATGGGTCAG-3′ [55]
R: 5′-TTTGATGTCACGCACGATTTCC-3′
IL-1β F: 5′-CAGGATGAGGACATGAGCACC-3′ [55]
R: 5′-CTCTGCAGACTCAAACTCCAC-3′
iNOS F: 5′-CCTCCTCCACCCTACCAAGT-3′ [56]
R: 5′-CACCCAAAGTGCTTCAGTCA-3′
CD200 F: 5′-TGTTCCGCTGATTGTTGGC-3′ [57]
R: 5′- ATGGACACATTACGGTTGCC-3′
CX3CR1 F: 5′-GGC CTT GTC TGA TCT GCT GTT TG-3′ [58]
R: 5′- AAT GCT GAT GAC GGT GAT GAA GAA-3′
MCP-1 F: 5′-AGCATCCACGTGCTGTCTC-3′ Universal ProbeLibraryb
R: 5′-GATCATCTTGCCAGTGAATGAG-3′
aCX3CR1, chemokine (C-X3-C motif) receptor 1; IL-6, Interleukin 6; iNOS, inducible nitric oxide synthase; MCP-1, monocyte chemoattractant protein 1; TNF, Tumour
necrosis factor. bRoche Applied Science (Indianapolis, IN, USA).
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Tween 20) for 1 hour at room temperature. Membranes
were then incubated using anti-cyclooxygenase 2 (anti-
Cox-2) antibody (1:1,000; Santa Cruz Biotechnology).
β-actin antibody (Sigma-Aldrich; 1:2,000) was used as a
loading control.Determination of lipid hydroperoxide by oxidation
of Fe2+ in presence of xylenol orange
The protocol for lipid peroxidation measurements [60]
was adapted for a microplate reader. Sample buffer
(10 μl) was incubated with 90 μl of H2SO4 for 30 mi-
nutes. After addition of 100 μl of FOX reagent (0.5 mM
ferrous ammonium sulphate, 200 mM sorbitol and
0.2 mM xylenol orange in 25 mM H2SO4), the mixture
was incubated at room temperature for 45 minutes while
protected from light. The formation of ferric ions was
detected by measuring the resulting coloured complex
formed by xylenol orange at 560 nm (ε = 4.3 × 104/M/cm).Statistical analysis
Results are expressed as mean ± SD. Means were com-
pared by using Student’s t-test (weight gain and serum
corticosterone levels) or analysis of variance (ANOVA)
followed by the least significant difference (LSD) test for
post hoc multiple range comparisons. The α value was
set at 0.05. STATGRAPHICS Plus 3.0 software was usedfor the calculations (Statpoint Technologies, Warrenton,
VA, USA).
Results
Validation of the stress model
Body weight gain alteration is a typical effect of stress
and is used as a method to assess stress models [46]. In
our experimental design, stressed animals gained 28.8%
less weight than controls (P < 0.05) (Figure 2A). Adrenal
gland weight increased 34.7% in stressed animals (P < 0.01)
(Figure 2B). The ratio of adrenal gland weight to body
weight gain increased by 94.0% in the stressed animals
compared with the controls (P < 0.01) (Figure 2B). Serum
levels of corticosterone were evaluated before stress and at
days 1, 3, 6 and 10 of the variate stressor paradigm. Be-
cause steroids levels are subjected to daily changes, blood
samples were collected between 09:00 and 10:00. As ex-
pected, there was a significant increase in corticosterone
levels that peaked at day 6 in stressed animals and de-
creased afterward (Figure 2C).
Activated microglia quantification and expression levels
of TNF-α, IL-6, IL-1β and iNOS mRNAs and COX-2 protein
Microglial cells become activated (that is, change of
morphology from resting resident ramified microglia with
two or three fine processes to round cells resembling
tissue macrophages) and proliferate when challenged.
Immunohistochemistry of Iba-1 and OX-6 showed that
injection of vehicle in nonstressed animals (controls)
Figure 2 Validation of the stress model. (A) Body weight gain
(in grams). *P < 0.05. (B) Adrenal gland weight (in milligrams; bars)
and ratio between adrenal gland weight and body weight gain
(scatterplot and line). **P < 0.01, #P < 0.01 (for adrenal gland weight/
body weight gain ratio). (C) Serum corticosterone (percentage of
control animals). *P < 0.01 compared with control, aP < 0.01 compared
with previous time point (S1d to S10d indicates days subjected to
variate stress). Statistical significance was calculated by using Student’s
t-test to compare data before (C) and after 10 days (S10d) of variate
stress. Data were derived from one-way analysis of variance followed
by the least significant difference (LSD) post hoc test for multiple
range comparisons.
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intense in stressed animals (approximately fivefold that
of controls; P < 0.001) (Figures 3 and 4). LPS injection
induced stronger activation in nonstressed animals (about
eightfold compared with control animals; P < 0.001). Com-
bination of stress and LPS produced an additive effect(nearly 15-fold increase over controls; P < 0.001) that
was reduced by RU486 (decreased ninefold from con-
trol values; P < 0.001).
Microglia in the SN were also studied at the molecular
level by RT-PCR to evaluate their activation under stress,
brain inflammation or both. Activated microglia produce
various cytokines and proinflammatory substances with
different actions, depending on the inductor of their ac-
tivation. Previous short-term temporal analysis revealed
that the highest induction of cytokines occurred 6 hours
after the LPS injection and decreased at 48 hours [61].
Hence, we measured the differences in the expression
profile of the cytokines in the ventral mesencephalon at
6 hours after the injection of LPS. Stress produced no
effect on TNF-α (Figure 5A), whereas LPS induced an
increase in its expression in nonstressed animals sevenfold
over control values (P < 0.001). When LPS was injected
into stressed animals, expression levels of TNF-α were
about 13-fold greater than control values (P < 0.001). The
expression levels of IL-1β in SN were not affected by
stress (Figure 5B) and increased after the injection of LPS
in both nonstressed and stressed animals (approximately
9- and 18-fold greater than control values, respectively;
P < 0.001). Similarly, the expression levels of IL-6 in SN
were not affected by stress (Figure 5C) and increased
after the injection of LPS in both nonstressed and
stressed animals (about 10- and 25-fold above control
values, respectively; P < 0.05). The expression levels of
iNOS in SN were not affected by stress (Figure 5D) and
increased after the injection of LPS in both nonstressed
and stressed animals (approximately 30- and 60-fold over
control values, respectively; P < 0.05). RU486 reduced the
expression levels of all parameters assayed to values close
to those induced by LPS in nonstressed animals.
The protein levels of COX-2 were measured by Western
blot analysis. As expected, LPS treatment increased the
expression levels of COX-2, by 33.1% (P < 0.05). Stress in-
duced a nonsignificant tendency to further increase the
protein levels of COX-2 in both vehicle- and LPS-injected
animals (data not shown).
In order to obtain direct proof that microglia are acti-
vated in a proinflammatory state and release proinflamma-
tory mediators, we performed double-immunofluorescence
with Iba-1 and IKKβ. As shown in Figure 6, most activated
microglial cells colocalized with IKKβ in the ventral
mesencephalon.
Effect lipopolysaccharide and stress on lipid peroxidation
To investigate the production of reactive oxygen species
(ROS) induced by stress, we determined lipid peroxidation
using a FOX assay. As shown in Figure 7, stress increased
the amount of lipid peroxides in both vehicle- and LPS-
injected animals (127 ± 6.18% and 165 ± 3.48% of control
values; P < 0.001).
Figure 3 Effect of chronic stress on the lipopolysaccharide-induced activation of microglia in the ventral mesencephalon. Midbrain
microglia were evaluated by immunohistochemistry with Iba-1 (left and middle columns) and OX-6 antibodies (right column) in vehicle-injected
animals (A) through (F) and lipopolysaccharide (LPS)-injected animals (G) through (L) under nonstressed conditions ((A) through C) and (G)
through (I)) and stressed conditions ((D) through (F) and (J) through (L)). Iba-1 immunohistochemistry is shown at low and high magnification
(left and middle columns, respectively). (M) through (O) The effect of RU486 (mifepristone (11β-[p-(dimethylamino)phenyl]-17β-hydroxy-17-(1-
propynyl)estra-4,9-dien-3-one)) on the microglia population in response to LPS injection in stressed animals. Note that stress highly increased
the microglial activation response to LPS injection (J) through (L) compared with nonstressed conditions (G) through (I). Note that, after LPS injection,
most microglial cells display a round morphology typical of macrophages, whose density significantly increases under conditions of chronic stress. Also
note how RU486 treatment strongly prevents the stress-induced sensitisation of microglia to subsequent LPS injection (M) through (O). The
blue staining in all panels is the Monastral Blue inert tracer contained in the vehicle. Scale bars: 500 μm (A, D, G, J and M); 100 μm (all other
panels). Abbreviations: V, Vehicle; S, Stress; SL, Lipopolysaccharide injected into stressed animals; SLR, Lipopolysaccharide injected into stressed
animals treated with RU486.
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expression levels
There is evidence that several molecules associate with
inhibitory actions on microglia, including CD200 and
CX3CR1. Hence, we decided to monitor these molecules
in our experimental conditions to seek further explanationsof how stress triggers an exacerbated response. The ex-
pression levels of CD200 mRNA in SN were reduced
after the injection of LPS into nonstressed animals
(29.6 ± 17% of control values; P < 0.05) (Figure 8A),
whereas these levels were increased after the injection
of LPS into stressed animals (185 ± 69.2% of control
Figure 4 Effect of lipopolysaccharide and stress on the number
of activated microglial cells in the substantia nigra. Quantification
of changes on the reactive microglial population in the substantia
nigra at the end of the treatments. Results are mean ± SD of four
independent experiments expressed as OX-6-positive cells/mm2.
P < 0.001 by one-way analysis of variance followed by the least
significant difference post hoc test for multiple range comparisons:
a, compared with vehicle (V); b, compared with stress (S); c, compared
with lipopolysaccharide (L); d, compared with stress + lipopolysaccharide
(SL). SLR, Lipopolysaccharide injected into stressed animals treated with
RU486 (mifepristone (11β-[p-(dimethylamino)phenyl]-17β-hydroxy-
17-(1-propynyl)estra-4,9-dien-3-one)).
Figure 5 Effect of lipopolysaccharide and stress on expression of tumo
oxide synthase mRNAs in substantia nigra. mRNA expression was qua
animals. As expected, lipopolysaccharide (LPS) injection increased the express
combined, whereas treatment with RU486 (mifepristone (11β-[p-(dimethylam
this effect. Results are mean ± SD of at least three independent experiments e
calculated by one-way analysis of variance followed by the least significant diff
vehicle (V); b, compared with stress (S); c, compared with lipopolysaccharide (L)
injected into stressed animals treated with RU486 (mifepristone (11β-[p-(dime
(A) Tumour necrosis factor α (TNF-α), P < 0.001. (B) Interleukin 1β (IL-1β),
synthase (iNOS), P < 0.01.
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mRNA in SN were reduced after the injection of LPS in
both nonstressed and stressed animals (48.7 ± 21.1% and
17.4 ± 10.2% of control values, respectively; P < 0.001)
(Figure 8B).
The MCP-1–CCR2 chemokine axis is an important
mediator of the migration of monocytes, memory T lym-
phocytes and natural killer cells into affected areas in
diseases such as multiple sclerosis, rheumatoid arthritis,
type 2 diabetes and Alzheimer’s disease [62,63]. Hence,
we decided to study the changes in the expression levels
of the chemokine MCP-1 in the SN of stressed and non-
stressed animals. Our results show that chronic stress
induces a dramatic increase in the mRNA expression of
MCP-1 in the SN of LPS-injected animals (P < 0.001)
(Figure 8C).
Astroglia population
We have previously shown that the intranigral injection
of LPS induces the loss of astroglia through a mech-
anism that is not yet well-known [26-28]. In our
present study, we found that there is slight astroglio-
sis around the vehicle injection site, without loss of
GFAP immunostaining, in nonstressed and stressedur necrosis factor α, interleukin 1β, interleukin 6 and inducible nitric
ntified by real-time RT-PCR. Stress had no effect in the vehicle-injected
ion levels of mRNA. This induction was higher when LPS and stress were
ino)phenyl]-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one)) prevented
xpressed as percentage of control values. Statistical significance was
erence post hoc test for multiple range comparisons a, compared with
; d, compared with stress + lipopolysaccharide (SL). SLR, Lipopolysaccharide
thylamino)phenyl]-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one)).
P < 0.001. (C) Interleukin 6 (IL-6), P < 0.01. (D) Inducible nitric oxide
Figure 6 Effect of stress and lipopolysaccharide on inhibitor of nuclear factor κΒ kinase, subunit β, and Iba-1 in the substantia nigra.
Iba-1 immunofluorescence (A), (D) and (G) and inhibitor of nuclear factor κΒ kinase, subunit β (IKKβ), immunofluorescence (B), (E) and (H) show
robust induction of IKKβ in Iba-1-labelled microglial cells in the merged images (C), (F) and (I). Images (A), (B) and (C) were taken of an animal
injected with lipopolysaccharide (LPS; L). Images (D) through (F) were taken of a stressed animal injected with LPS (SL). Images (G), (H) and (I)
are high-magnification photomicrographs showing one representative cell. Scale bars: (A) through (F), 200 μm; (G) through (I), 25 μm. Arrows
indicate colocalizing cells.
Figure 7 Effect of stress and lipopolysaccharide on lipid
peroxidation in the substantia nigra. Lipid peroxidation increased
in stressed animals as well as after the injection of lipopolysaccharide
(LPS) in nonstressed animals. When combined, stress and LPS had an
additive effect. P < 0.01 by one-way analysis of variance followed by
least significant difference post hoc test for multiple range comparisons.
a, compared with vehicle (V); b, compared with stress (S); c, compared
with lipopolysaccharide (L). SL, stressed animals injected with
lipopolysaccharide.
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around the LPS injection site, an area absent of GFAP-
positive structures (0.67 mm2; P < 0.001 compared with
control animals) but surrounded by hyperreactive astro-
cytes (Figures 9C, 9D and 9G). Stress and LPS interact in
a synergistic manner, producing an increase in the area
lacking astrocytes (1.15 mm2; P < 0.001 compared with
control animals) (Figures 9E, 9F and 9G). This effect was
not reduced by RU486 (1.17 mm2 (Figure 9G).
Dopaminergic neurons
TH immunostaining was carried out to detect DAergic
neurons. An even distribution was seen in the SN of
nonstressed and stressed animals injected with vehicle
(Figures 10A and 10B). As we have previously shown,
the intranigral injection of LPS produced a decrease in
the number of DAergic neurons around the injection
site (55.6% of controls; P < 0.001) (Figure 10C). When
LPS was injected into stressed rats, its effect was stronger,
decreasing the number of neurons to 27.1% of that of con-
trols (P < 0.001) (Figure 10D). This effect was reduced by
RU486 (69.0% of controls; P < 0.001) (Figure 10E). In
order to demonstrate the presence of morphologically
Figure 8 Effect of stress and lipopolysaccharide on the expression
of CD200, chemokine (C-X3-C motif) receptor 1 and monocyte
chemoattractant protein 1 mRNAs in the substantia nigra.
mRNA expression was quantified by real-time RT-PCR. (A) CD200.
Lipopolysaccharide (LPS) decreased CD200 expression in nonstressed
animals and increased it in stressed rats. (B) Chemokine (C-X3-C
motif) receptor 1 (CX3CR1). LPS decreased CX3CR1expression in
nonstressed animals, and in stressed animals the decrease was
even greater. (C) Monocyte chemoattractant protein 1 (MCP-1). No
significant change was observed after injection of LPS into nonstressed
rats. However, the effect of LPS on MCP-1 expression in stressed
animals was massive. P < 0.01 by one-way analysis of variance
followed by least significant difference post hoc test for multiple
range comparisons. a, compared with vehicle (V); b, compared with
lipopolysaccharide (L). SL, stressed animals injected
with lipopolysaccharide.
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onal density, we performed double-immunostaining of
TH and Iba-1 (Figures 10G, 10H and 10I). Our resultsshow that, in the areas with activated microglia, the TH-
immunopositive cells are scarce and have a degenerative
morphology.
Discussion
In our present study, we show that chronic stress ex-
acerbates microglial activation after injection of a pro-
inflammatory stimulus such as LPS in the ventral
mesencephalon, leading to an increase in the death of
DAergic neurons in the SN. This effect was glucocorticoid
(GC)-dependent because treatment with the GR antag-
onist RU486 prevented stress-induced microglial over-
activation and the subsequent higher neuronal death in
response to LPS.
In a previous study, our group showed that chronic
stress strengthened the inflammatory stimulus associated
with a single LPS injection in limbic areas such as the
PFC, and, more important, induced extensive neuronal
loss [44]. The injection of LPS into the PFC induced a
moderate inflammatory response compared with injec-
tion into the SN [26,44]. Similar results were found
when LPS was injected into the hippocampi of stressed
animals [43]. However, contrary to the effect observed in
the PFC, the hippocampus was totally resistant to the
proinflammatory reaction induced by LPS in the absence
of stress. Consistently, our study results suggest that
stress strongly sensitises microglial cells to proinflamma-
tory stimuli in limbic areas, which express high levels of
GR [64]. It is unknown if this is a general effect in the
CNS. Consequently, the aim of the present study was to
elucidate whether microglial sensitisation by stress in
the hippocampus and the PFC is extensible to other
CNS structures, especially those involved in neurodegen-
erative disorders in which inflammation seems to play
an important role [65]. To test this hypothesis, we per-
formed intracerebral injection of LPS into the SN, which
is characterized by a high density of microglia [66]. This
feature makes the SN highly reactive to proinflammatory
stimuli. The degeneration of the nigral DAergic system
is the most important distinguishing characteristic of PD.
Our study shows that there is an important neurode-
generative process in the SN of stressed animals after
the injection of LPS. Stereological analysis revealed a sig-
nificant effect of chronic stress, reinforcing the loss of
TH-immunopositive neurons induced by LPS. In a pre-
vious study, Smith et al. [67], by using the 6-OHDA
model of PD, showed that chronic psychological stress
accelerates neural degeneration, suggesting that stress
could be an aggravating factor in DAergic degeneration.
The question that remains is how chronic stress sensi-
tises DAergic neurons to further damage. To answer this
question, we used a model of DAergic degeneration
based on brain inflammation in the ventral mesenceph-
alon induced by a single intranigral injection of LPS.
Figure 9 Effect of stress and lipopolysaccharide in astroglia in the substantia nigra. (A) Coronal section showing glial fibrillary acidic protein
(GFAP) immunoreactivity in a vehicle-injected nonstressed animal (arrow points to injection site). A limited alteration restricted to the needle tract
is observed. (B) High-magnification image of the area within the box in (A). (C) GFAP immunoreactivity in a lipopolysaccharide (LPS)-injected
nonstressed animal. There is an area lacking GFAP immunoreactivity around the injection track (dotted encircled area). (D) High-magnification
image of the square box in (C); the arrow shows the injection site. (E) GFAP immunoreactivity in a LPS-injected stressed animal. The area lacking
GFAP immunoreactivity is bigger (dotted encircled area). (F) High magnification of the square box in panel E showing hypertrophic astrocytes
surrounding the injection site. Scale bars: (A), (C) and (E), 500 μm; (B), (D) and (F), 100 μm. Abbreviations: V, vehicle; S, stress; L, lipopolysaccharide; SL,
lipopolysaccharide injected into stressed animals; SLR, lipopolysaccharide injected into stressed animals treated with RU486 (mifepristone
(11β-[p-(dimethylamino)phenyl]-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one)). (G) Quantification of the areas lacking GFAP immunoreactivity on
the substantia nigra at the end of the treatments. Results are mean ± SD of at least four independent experiments expressed in millimetres squared.
P < 0.001 by analysis of variance followed by least significant difference post hoc test for multiple comparisons. a, compared with vehicle (V); b,
compared with stress (S); c, compared with lipopolysaccharide (L). SL, stressed animals injected with lipopolysaccharide; SLR, lipopolysaccharide
injected into stressed animals treated with RU486.
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stress and LPS significantly increased microglial activa-
tion compared with LPS alone, an indication that stresssensitises microglia in brain areas other than limbic
structures such as the hippocampus and the PFC. A typ-
ical feature of Toll-like receptor ligation is activation of
Figure 10 Chronic stress increases the lipopolysaccharide-induced loss of dopaminergic neurons in the substantia nigra. (A) Coronal
section showing tyrosine hydroxylase (TH) immunoreactivity after the injection of vehicle (arrow) in nonstressed animals. (B) TH immunoreactivity
after the injection of vehicle (arrow) in stressed animals. No significant changes can be observed. (C) TH immunoreactivity after the injection of
2 μg of lipopolysaccharide (LPS) into the substantia nigra (SN) of nonstressed rats. There is a loss of dopaminergic neurons around the injection
track (arrow). (D) TH immunoreactivity after the injection of 2 μg of LPS into the SN of stressed rats. The loss of neurons is higher around the
injection track (arrow). (E) RU486 (mifepristone (11β-[p-(dimethylamino)phenyl]-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one)) diminished the loss
of TH-positive neurons caused by the combined action of LPS and stress. Scale bar: 500 μm. Abbreviations: V, vehicle; S, stress; L, lipopolysaccharide; SL,
lipopolysaccharide injected into stressed animals; SLR, lipopolysaccharide injected into stressed animals treated with RU486. (F) Quantification of the
number of TH-positive cells. Results are mean ± SD of four independent experiments expressed as TH-positive cells within the bounded area of the SN.
P < 0.001 by analysis of variance followed by least significant difference post hoc test for multiple comparisons. a, compared with V; b, compared with
S; c, compared with L; d, compared with SL. (G) Immunofluorescence of TH after the injection of 2 μg of LPS into the SN of stressed rats.
(H) Immunofluorescence of Iba-1 after the injection of 2 μg of LPS into the SN of stressed rats. (I) Merged image of (G) and (H) showing
activated microglia around the dopaminergic neurons. Scale bars in (G) through (I): 100 μm.
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of proinflammatory genes [65]. Activation of NF-κB re-
lies on activation of the IKK complex, in which IKKβ
triggers the canonical pathway. We have previously shown
that LPS induces IKKβ expression in reactive microglia
similarly to iNOS, as revealed by Western blot analysis
and quantitative PCR [68]. In our present study, we per-
formed dual-immunofluorescence detection of Iba-1 and
IKKβ in the ventral mesencephalon in response to intrani-
gral LPS injection to further test whether microglia were
indeed activated and thus capable of releasing proinflam-
matory mediators responsible for the death of DAergic
neurons. Our immunohistochemical data demonstrate ro-
bust induction of IKKβ in Iba-1-labelled microglia in the
ventral mesencephalon in response to LPS injection in the
absence or presence of chronic stress, thus demonstrating
proinflammatory gene expression in LPS-induced reactive
microglia. ROS generation is another hallmark of neuro-
toxic microglia, which readily attack numerous biomole-
cules, including lipids, nucleic acids and proteins. We
wanted to know whether LPS would increase the oxida-
tion status of mesencephalic tissue and whether chronic
stress would alter the expected LPS-induced free radical
generation. Toward this end, we quantified lipid peroxida-
tion in mesencephalic tissue using a FOX assay. As ex-
pected, LPS significantly increased lipid peroxidation, and,
more important, chronic stress further increased this
effect, in keeping with its deleterious effect on the DAergic
system. Real-time PCR shows an increase in the mRNA
expression levels of different inflammatory mediators, in-
cluding IL-6, TNF-α, IL-1β and iNOS, 6 hours after the
treatment with LPS, which was further elevated in the
LPS-injected animals under chronic stress. These findings
are suggestive of microglia priming. When priming does
occur in microglia or peripheral macrophages, these
sensitised cells do not produce proinflammatory or anti-
inflammatory products, but, if further stimulated, they
produce high levels of proinflammatory products [69-75].
GCs are generally regarded as anti-inflammatory and
indeed have a variety of actions that inhibit inflamma-
tion. However, it is known that the temporal relationship
between GC treatment and immune challenge may be
an important factor in determining whether GCs exhibit
pro- or anti-inflammatory properties. To shed light on
this issue, we studied the mRNA expression of CD200
and CX3CR1 (also known as fractalkine receptors),
which have been associated with inhibitory actions on
brain microglia [76], and MCP-1, a potent chemokine
which has been implicated in different neurological
disorders [77]. CD200 is an extrinsic factor widely
expressed not only on neurons but also on astrocytes
and oligodendrocytes [78]. Its receptor, CD200R, is
expressed exclusively on macrophages in the CNS, in-
cluding microglia. The interaction of neuronal CD200with CD200R leads to inactivation of microglia and
keeps them in a resting state [79,80]. As expected, intra-
nigral LPS injection led to significant downregulation of
CD200 mRNA expression in the ventral mesencephalon.
However, chronic stress turned the LPS-induced down-
regulation of CD200 expression into significant upregu-
lation of this extrinsic microglia regulator, thus excluding
CD200 as a physiological stress-related molecule respon-
sible for activating microglia. In the CNS, microglia are
the only cells that express CX3CR1 [81]. Cardona et al.
[81], using CX3CR1+/− and CX3CR1−/− mice, demon-
strated an inverse relationship between CX3CR1 expres-
sion and neurotoxic activation of microglia in three
different models of neurodegeneration, including the
MPTP model of PD, a transgenic model of amyotrophic
lateral sclerosis, and systemic LPS injections. Our data
demonstrate that intranigral LPS injection significantly
decreased CX3CR1 expression. Strikingly, chronic stress
further strengthened LPS-induced CX3CR1 downregu-
lation. It will be very important to discover whether
physiological stress downregulates CX3CR1 expression
in different animal models of neurodegeneration, taking
into consideration the role of CX3CR1 as a selective
regulator of microglial neurotoxicity in vivo.
MCP-1 is the most potent activator of signal transduc-
tion pathways leading to monocyte transmigration [82].
There is strong evidence that MCP-1 is involved in the
recruitment of monocytes, macrophages and activated
lymphocytes into the CNS [83]. Of note, chronic stress
dramatically increased the LPS-induced expression of
MCP-1 in the mesencephalon, which may facilitate the
infiltration of peripheral immune cells. In support of this
observation, chronic stress has been shown to stimulate
the expression of MCP-1 along with infiltration of bone
marrow-derived microglia into the paraventricular nu-
cleus [84]. Taken together, our results demonstrate that
chronic stress modulates key molecules regulating brain
inflammation, which opens the potential for strategies
aimed at minimising its deleterious effects.
Frank et al. [69] showed that, when corticosterone was
administered 2 hours before LPS injection, corticosterone
was unable to inhibit hippocampal cytokine responses po-
tentiating the production of IL-6. In our experimental
conditions, LPS was injected 2 hours after the introduc-
tion of the first stressor (forced swimming). It is known
that, immediately after acute forced swimming stress, cor-
ticosterone levels increase in plasma [85]. This suggests
that stress sensitises (that is, primes) midbrain microglia
to subsequent proinflammatory stimuli. Consistent with
our results, other studies have shown that exposure to
stressors increases the immune activation state in the
CNS. For example, Nair and Bonneau [86] showed that
chronic restraint stress increased microglial proliferation
and microglial activation. Taking into consideration our
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present results are consistent with the view that stressors
sensitise the neuroinflammatory response to central im-
munological challenges.
Ros-Bernal et al. [87] studied the involvement of GC-
GR in MPTP-lesioned mice in terms of DAergic loss
and microglial activation. Using conditional GC-CR-
knockout mice in the myeloid cell lineage, including
microglia and peripheral macrophages, they found
higher loss of TH-positive neurons in the SN of knock-
out mice, as well as higher reactive microgliosis than
that in wild-type mice. Further, proinflammatory genes
were significantly upregulated in the conditional GC-
GR-knockout mice [87]. These findings are good exam-
ples of how acute and chronic stress may have opposite
effects in terms of brain inflammation and associated
neurodegeneration. Our model of chronic stress was val-
idated in three different ways; time course of cortico-
sterone levels, body weight loss and hypertrophy of
adrenal glands. Besides, we had previously measured
dopamine release in the PFC under the same stress para-
digm [44]. Overall, our data demonstrate a persistent
elevation of GC (9 days) covering the period from the
intranigral LPS injection to the immunohistochemical
data analysis. In fact, the most plausible mechanism
associated with our chronic stress paradigm is the long-
lasting increase in systemic GC associated with activa-
tion of the HPA axis. To prove this hypothesis, we tested
the ability of RU486 (mifepristone, a potent inhibitor of
GR activation and also an antagonist of the progesterone
receptor) to counteract the aggravating effect of chronic
stress on the LPS-induced death of nigral DAergic neu-
rons. We have used a dose of 20 mg/kg RU486, as we and
others have reported previously [43,44,88-90]. Treatment
with RU486 significantly protects nigral TH-positive
neurons from the damage observed in stressed animals
injected with LPS. Importantly, treatment with RU486
prevented the “priming effect” associated with stress in
terms of activated microglia and expression of proin-
flammatory markers in response to intranigral LPS.
Altogether, these data show that GCs play a critical role
in the activation of microglia in response to LPS, lead-
ing to increased neuronal death in the SN.
There is no clear evidence of a causal relationship be-
tween stress (and stress hormones) and PD. However, an
increasing base of data suggests that they could be an
important factor in its pathogenesis. GR density is not
equal in all brain structures, and, interestingly, it is
higher in regions that are involved in motor control,
such as the motor cortex, basal ganglia and cerebellum
[91,92]. This makes these areas more susceptible to the
effects of stress, so that stress and stress hormones affect
the function of intact (that is, undamaged) motor sys-
tems in both humans [93] and rats [94,95]. This is alsoobserved in PD patients, with a positive association be-
tween cortisol and gait deficits [96]. It has been shown
that immobilization stress increases oxidative stress and
that this selectively damages the DAergic system [97].
This is consistent with studies showing that the DAergic
system is particularly sensitive to stress [98-100]. How-
ever, it seems that the greatest risk factor for the devel-
opment of PD is age, which could contribute to a
deterioration of the compensatory mechanisms that ex-
tends along with the preclinical stages of the disease
[101,102]. Also, there is an alteration in the response to
stress during aging. For example, the response of the
HPA axis to stress is higher, and its return to homeo-
static conditions is slower, so that cells are exposed to
high levels of GCs for a longer period (see [103] for a
review). The deregulation of these processes could be
related to the higher sensitivity of the DAergic neurons
to damage, causing neurons of certain brain areas to be
more susceptible to degeneration during stress episodes.
Conclusions
Our data show that chronic stress exacerbates microglial
activation and the death of DAergic neurons after an
inflammatory challenge to the ventral midbrain, suggest-
ing that stress may be an important factor in the degen-
erative processes in and the development of symptoms
of PD. Therefore, new strategies to reduce the effect of
stress should be explored for the prevention and treat-
ment of PD and other neurodegenerative conditions.
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